Publishers Note: Researcher Associate Professor Jeff Babon advises: This is very early stage research.  It gives us the blueprint to begin to develop a medicine that targets the molecule, JAK2, that is responsible for PV and other MPNs in a novel way, the same way that is used by own our natural JAK2-inhibitory protein (called SOCS1). […]